2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Ovarian Neoplasms
69
Neoplasms
21
Breast Neoplasms
21
Fallopian Tube Neoplasms
18
Prostatic Neoplasms
15
Neoplasm Metastasis
9
Pancreatic Neoplasms
8
Endometrial Neoplasms
8
Carcinoma, Ovarian Epithelial
8
Glioblastoma
7
Triple Negative Breast Neoplasms
6
Lung Neoplasms
5
Small Cell Lung Carcinoma
4
Glioma
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Mesothelioma
3
Melanoma
3
Head and Neck Neoplasms
3
Cystadenocarcinoma, Serous
3
Cholangiocarcinoma
3
Carcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Sarcoma
2
Prostatic Neoplasms, Castration-Resistant
2
Ovarian Diseases
2
Interventions
Cisplatin
180
Radiotherapy
81
Paclitaxel
80
Brachytherapy
74
Carboplatin
72
pembrolizumab
63
Bevacizumab
40
Surveys and Questionnaires
29
Colposcopy
29
Radiation
28
Gemcitabine
28
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
27
Topotecan
26
Magnetic Resonance Spectroscopy
24
Blood Specimen Collection
23
human papillomavirus vaccine, L1 type 16, 18
22
Nivolumab
22
Drug Therapy
21
Papillomavirus Vaccines
20
atezolizumab
19
Platinum
19
Radiotherapy, Intensity-Modulated
18
Biopsy
18
Docetaxel
17
Taxes
16
Cyclophosphamide
16
Early Intervention, Educational
15
1,2-diaminocyclohexaneplatinum II citrate
15
Methods
14
fludarabine
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
niraparib
×
Clear all
NCT04068753
2026-02-10
STAR
University of Oklahoma
Phase 2
Active not recruiting
66 enrolled
NCT03644342
2024-09-03
NIVIX
Baylor College of Medicine
Phase 1/2
Terminated
4 enrolled
8 charts